Skip to main
BBNX

BBNX Stock Forecast & Price Target

BBNX Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 27%
Hold 27%
Sell 0%
Strong Sell 0%

Bulls say

Beta Bionics is uniquely positioned in the market due to the potential of its revolutionary iLet Bionic Pancreas technology in the treatment of diabetes. The company has demonstrated consistent financial growth with a steady cadence of "beats and raises" and has a strong product offering with the iLet and Mint. Investors can expect a focus on cost reduction and continued sales force expansion to drive further revenue growth in the coming years.

Bears say

Beta Bionics is making progress in the development and launch of its iLet Bionic Pancreas and Mint patch pump, with an updated algorithm expected for launch in 4Q26. The company has received FDA clearance for Mint, which is expected to launch in 1Q27 and contribute to revenue growth. However, the company's financials remain a concern, with a negative adjusted EBITDA expected for FY26 and lowered revenue guidance due to a potential shift in patient launch preferences. As a financial analyst, a cautious approach is recommended towards this stock until there is more clarity on the company's financial performance and ability to generate profits.

BBNX has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 27% recommend Buy, 27% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Beta Bionics Inc (BBNX) Forecast

Analysts have given BBNX a Buy based on their latest research and market trends.

According to 11 analysts, BBNX has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Beta Bionics Inc (BBNX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.